For Mercodia, progress depends not only on scientific excellence, but also on connecting knowledge and remaining open to new perspectives.

“The next important idea may come from a researcher, a biotech company, a technology specialist or an unexpected direction. Innovation happens when different perspectives meet,” says Jörgen Dahlström, CEO of Mercodia.

“The question is not whether the next breakthrough will happen. The question is whether we will be connected to it when it does.”

The risk of working in isolation

Life science organizations are accustomed to managing scientific, regulatory, and operational risk. Yet another risk receives less attention: the risk of working in isolation.

No organization can hold all the knowledge needed to navigate today’s scientific landscape. Biology is becoming more complex, technology is evolving rapidly, and know-how is increasingly distributed. When that know-how is not exposed to new thinking, important questions may go unasked and opportunities may be overlooked. 

Collaboration brings complementary knowledge together and challenges assumptions. It is about creating the conditions to ask better questions. At its best, it helps organizations see more of the problem and ultimately create better possibilities for solving it. 

Choosing openness

For more than 35 years, Mercodia has built deep scientific expertise and developed trusted immunoassays and bioanalytical solutions for researchers, pharmaceutical companies and biotechnology companies. But expertise alone is not enough in a rapidly changing life science landscape. Scientific progress also depends on curiosity, openness and a willingness to explore new perspectives.

At Mercodia, this approach is captured in three principles: build on expertise, innovate through curiosity and partner with purpose. 

That means being confident in what we know while remaining curious about what we do not. It means learning from researchers, customers, partners and new technologies without compromising confidentiality, intellectual property or scientific integrity.

From analytical expertise to scientific partnership

As drug development programmes become more specialized, companies need partners who understand the scientific context, not just the technical requirements. 

For Mercodia, this means seeking to understand the scientific question behind a project rather than simply completing the analytical task. The ambition is to contribute knowledge, technology and new perspectives, while allowing our own thinking to be challenged.

A good partnership is not about thinking alike. It is about bringing together different specialities, experiences and perspectives in pursuit of a common goal. By broadening our understanding of the challenge, we improve our ability to find meaningful solutions. 

Creating the conditions for what comes next

This way of working shapes how Mercodia engages with researchers, drug developers and partners across the life science ecosystem. 

“We do not know where the next breakthrough will come from. What we can do is remain open and create the conditions for valuable perspectives to meet,” Dahlström concludes. 

about mercodia

Mercodia develops immunoassays and provides bioanalytical services, with expertise in biomarkers related to diabetes and cardiometabolic disease. 

Connect with Mercodia to explore opportunities for collaboration: mercodia.com